Zhejiang Medicine to use idle funds for investments

Zhejiang Medicine Co., Ltd. (SSE:600216) announced its intention to use no more than CNY 1 billion or 10% of its latest audited net assets (whichever is higher) in idle self-owned funds for entrusted financial management. This decision, approved by the company's board on May 30, 2025, will allow the funds to be invested in secure, liquid, and stable low-to-moderate risk short-term financial products, including bank wealth management products, securities firms' wealth management products, and other types of wealth management products. The investment period is valid for 12 months from the date of board approval, during which the funds can be used on a revolving basis. The company aims to improve the utilization rate of its funds, and it will adhere to the provisions of accounting standards for accounting and reporting, subject to the results of the annual audit.